SCHEDULE: Biotech Fund Adjusts Stoke Therapeutics Stake

Several Biotechnology Value Fund entities and Mark N. Lampert have filed a Schedule 13G, reporting changes in their beneficial ownership of Stoke Therapeutics, Inc. common stock.

Summary

• This filing is a Schedule 13G, indicating a change in beneficial ownership of Stoke Therapeutics, Inc. common stock by various Biotechnology Value Fund entities and Mark N. Lampert.
• The filing details the aggregate beneficial ownership of these entities as of September 30, 2026.
• The total beneficial ownership reported by Mark N. Lampert and associated entities is 3,608,968 shares, representing approximately 5.6% of the outstanding common stock.
• This percentage is based on 64,526,242 shares outstanding as of July 30, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as neutral to slightly negative, as it primarily reports a change in beneficial ownership percentage without new operational or financial disclosures.

Positives

• The filing confirms that the reporting persons do not hold the securities for the purpose of changing or influencing control of the issuer.

Negatives

• The filing does not contain any new operational or financial performance data for Stoke Therapeutics, Inc.

Risks

• The reporting persons' significant stake could potentially influence future corporate actions or strategic decisions of Stoke Therapeutics, Inc.

Future Outlook

No forward-looking statements or guidance are provided in this filing.

Management Comments

• Each of Partners, BVF Inc. and Mr. Lampert disclaims beneficial ownership of the Shares beneficially owned by BVF, BVF2 and Trading Fund OS and held in the Partners Managed Account, and the filing of this statement shall not be construed as an admission that any such person or entity is the beneficial owner of any such securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for investment funds and large shareholders to report changes in their holdings. This particular filing indicates a significant, but not controlling, stake in a biotechnology company, a sector often characterized by substantial institutional investment.

Stakeholder Impact

• Shareholders may monitor the actions of Biotechnology Value Fund entities and Mark N. Lampert due to their significant ownership stake.

Next Steps

• The reporting persons will continue to file amendments to Schedule 13G as required by SEC regulations.

Key Dates

Keywords

Stoke Therapeutics, Schedule 13G, Beneficial Ownership, Biotechnology Value Fund, Mark N. Lampert, Common Stock, Investment Management